ARTICLE | Clinical News
Emixustat: Phase IIa data
June 8, 2015 7:00 AM UTC
The double-blind, U.S. Phase IIa 4429-201 trial in 72 patients with GA associated with dry AMD showed that emixustat suppressed the recovery of rod photoreceptor responses from baseline to day 14 by 2...